首页> 外文OA文献 >Variability of Viral Load in Plasma of Rhesus Monkeys Inoculated with Simian Immunodeficiency Virus or Simian-Human Immunodeficiency Virus: Implications for Using Nonhuman Primate AIDS Models To Test Vaccines and Therapeutics
【2h】

Variability of Viral Load in Plasma of Rhesus Monkeys Inoculated with Simian Immunodeficiency Virus or Simian-Human Immunodeficiency Virus: Implications for Using Nonhuman Primate AIDS Models To Test Vaccines and Therapeutics

机译:猿猴免疫缺陷病毒或猿猴人类免疫缺陷病毒接种的恒河猴血浆中病毒载量的变异性:使用非人类灵长类艾滋病模型测试疫苗和治疗药物的意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Viral RNA level in plasma is a sensitive experimental endpoint for evaluating the efficacy of AIDS vaccines or therapies in nonhuman primates. By quantifying viral RNA in the plasma of 77 rhesus monkeys for 10 weeks after inoculation with simian-human immunodeficiency virus 89.6P (SHIV-89.6P) or simian immunodeficiency virus mac 251 (SIVmac 251), we estimated variability in three viral load (VL) measures: peak VL, the postacute set point VL, and VL decline from peak. Such estimates of biological variability are essential for determining the number of animals needed per group and may be helpful for selecting the most appropriate measure to use as the experimental endpoint. Peak VL was positively correlated with set point VL for both viruses. Variability (standard deviation) was substantially higher in monkeys infected with SIVmac 251 than in those infected with SHIV-89.6P for set point VL and VL decline. The variability of peak VL was less than one-half that of set point VL variability and only about two-thirds of that of VL decline, implying that the same treatment-related difference in peak VL could be detected with fewer animals than set point VL or VL decline. Thus, differences in VL variability over the course of infection and between viruses need to be considered when designing studies using the nonhuman primate AIDS models.
机译:血浆中病毒RNA水平是评估AIDS疫苗或非人灵长类动物疗法疗效的敏感实验终点。通过定量接种猿猴-人类免疫缺陷病毒89.6P(SHIV-89.6P)或猿猴免疫缺陷病毒mac 251(SIVmac 251)后77周恒河猴血浆中的病毒RNA,我们估算了三种病毒载量(VL )措施:峰值VL,后急性设定点VL和VL从峰值下降。这种对生物变异性的估计对于确定每组所需的动物数量至关重要,并且可能有助于选择最合适的措施用作实验终点。两种病毒的峰值VL与设定值VL正相关。在设定点VL和VL下降的情况下,感染SIVmac 251的猴子的变异性(标准差)明显高于感染了SHIV-89.6P的猴子。峰值VL的变异性小于设定点VL变异性的一半,而只有VL下降的三分之二,这意味着与设定点VL相比,用更少的动物就能检测到相同的治疗相关的VL峰值差异或VL下降。因此,在设计使用非人类灵长类AIDS模型的研究时,需要考虑感染过程中以及病毒之间VL变异性的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号